Global Peptic Ulcer Drugs Market Size To Expand At A Moderate CAGR Of 3.8% During The Forecast Period Of 2016-2022

Peptic Ulcer Drugs Market Overview:

Advancement in technology is aiding the pharmaceutical sector for development of highly effective drugs that are used for treating multiple disorders. Peptic ulcer drugs are used to treat the ulcer caused due to imbalance between defensive and aggressive fluids in the stomach. Market Research Future (MRFR) has published a report stating that the global peptic ulcer drugs market is marked to expand at a moderate CAGR of 3.8% during 2016-2022 and reach the valuation of USD 36.27 Bn by the end of 2022 from USD 29 Bn in 2015.

Get Free Sample copy @ https://www.marketresearchfuture.com/sample_request/2445

Peptic Ulcer Drugs Market Drivers and Restraints:

Changing lifestyle and food habits are majorly affecting the healthy functioning of gastric fluids, causing imbalance, which is then leading to various disorder such as ulcers. Increasing prevalence of lifestyle induced disorders and availability of effective drugs for treating such disorders are majorly fueling the expansion of the global peptic ulcer drugs market. Utilization of advanced technology for process automation of drug development in pharmaceutical industries and increase in research and development expenditure are some other factors that are propelling the growth of the global peptic ulcer drugs market. On the flip side, poor primary health care services and lack of awareness among the population in the underdeveloped regions are likely to pose a threat for the expansion of the global peptic ulcer drugs market during the forecast period.

Peptic Ulcer Drugs Market Segmentation:

The global peptic ulcer drugs market is segmented on the basis of pharmacological class and clinical application. Based on pharmacological class, the global peptic ulcer drugs market has been segmented into proton pump inhibitors (PPIs), anti-histamines, H2 antagonists, antacids, antibiotics and others. With respect to market valuation, the proton pump inhibitors (PPIs) segment is anticipated to project dominance over the global peptic ulcer drugs market during the forecast period. Based on clinical application, the global peptic ulcer drugs market has been segmented into gastric ulcers, duodenal ulcers and esophageal ulcer.

Peptic Ulcer Drugs Market Regional Analysis:

Geographically, the global peptic ulcer drugs market has been segmented into four major regions such as North America, Asia Pacific, Europe, and the Middle East and Africa. The North America region is projected to be the largest market for peptic ulcer drugs owing to the rapid adoption of advanced technology and automation of processes for drug manufacturing in pharmaceutical industry and increasing prevalence of ulcer and other intestinal disorders as a result of changing lifestyle and unhealthy food habits in this region. The peptic ulcer drugs market in the Europe region is projecting to expand at a significant growth rate during the forecast period owing to the increased research activities for the development of more effective drugs to cure peptic ulcers.

The Asia Pacific region is anticipated to expand at the fastest growth rate in the global peptic ulcer drugs market owing to the increasing demand for high-quality drugs to cure intestinal disorders and rapid development of healthcare sector in the emerging economies of this region. The Middle East and Africa region is projecting steady growth in the global peptic ulcer drugs market owing to the lack of awareness and poor healthcare facilities in the underdeveloped areas of this region.

Industry Updates:

In March 2018, Zydus Cadila, an Indian pharmaceutical company, has announced that it has received approval from US Food and Drug Administration (FDA) for marketing their new drugs, Omeprazole and Sodium bicarbonates capsules, that are used for treating esophagus and stomach problems such as peptic ulcers.

In February 2018, Stride Shasun, a key player in the U.S. Ranitidine market, has announced that it has decided to launch the over the counter version of intestinal and stomach ulcer drugs in 150 mg dosage which is now available for purchase in the U.S. market.

Key players:

The key players profiled by MRFR that are operating in the global peptic ulcer drugs market are Novartis AG, Daiichi Sankyo Company Limited, Actelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca plc, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc. Helicure AB and Eumedica Pharmaceuticals

Read More @ https://www.marketresearchfuture.com/reports/peptic-ulcer-drugs-market-2445

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

This release was published on openPR.